Bank of America Merrill Lynch Maintains Buy on Pfizer

Bank of America Merrill Lynch is out with its report today on Pfizer PFE, maintaining Buy. In a note to clients, Bank of America Merrill Lynch writes, "Pfizer offers compelling valuation, an attractive dividend yield, and the potential for the ongoing strategic review to lead to actions that could enhance shareholder value, in our view. Pipeline progress and business development deals are also key drivers." Bank of America Merrill Lynch maintains a $25 PO on PFE. At the time of posting, shares of PFE were trading at $20.36, down 0.34% from Tuesday's close.